EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioNTech SE's EBITDA for the
three
months ended in Mar. 2026 was $-512 Mil. BioNTech SE's Revenue for the
three
months ended in Mar. 2026 was $137 Mil. Therefore, BioNTech SE's EBITDA margin for the quarter that ended in Mar. 2026 was -374.94%.
BioNTech SE (NAS:BNTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioNTech SE EBITDA Margin % Related Terms
BioNTech SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioNTech SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNTX vs RPRX, INSM, ROIV: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioNTech SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioNTech SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a EBITDA Margin % of -374.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioNTech SE and its competitors. According to the industry distribution chart, BioNTech SE ranks #379 out of 945 companies in the Biotechnology industry, placing it in the top 40.1%.
Is BioNTech SE's EBITDA Margin % too high?
BioNTech SE's current EBITDA Margin % is -374.94%. Based on the distribution chart, BioNTech SE ranks #379 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's EBITDA Margin % compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #379 out of 945 companies for EBITDA Margin %. This puts BioNTech SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioNTech SE and its competitors. BioNTech SE's current EBITDA Margin % is -374.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $89.10, compared to a current price of $90.00 — trading 1% above its estimated fair value. The current EBITDA Margin % is -374.94%. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioNTech SE (BNTX), the current EBITDA Margin % is -374.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $90.00 is trading 1% above its estimated GF Value™ of $89.10.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
EBITDA Margin %: -374.94%
GF Value™: $89.10 vs. price of $90.00 (1% above fair value)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
